Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders

Abstract

Described herein are methods of treating neuron inflammation conditions, for example, amyotropic lateral sclerosis and prion disease, comprising administering a therapeutically effective amount of a combination of cromolyn or a cromolyn derivative compound and an anti-inflammatory agent.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Application No. 62 / 654,772, filed April 9, 2018, the entire contents of which are incorporated herein by reference. Background technique [0003] Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a specific disease that causes the death of neurons that control voluntary muscles. ALS is characterized by muscle stiffness, muscle twitching, and progressively worsening weakness due to a decrease in muscle size. This can cause difficulty speaking, swallowing, breathing and eventually death. [0004] ALS is estimated to affect as many as 30,000 people in the United States, with 5,000 new cases diagnosed each year. Most people with ALS are between the ages of 40 and 70, although the disease can occur at a younger age. Global ALS prevalence was independent of race, ethnicity, or socioeconomic group. ALS is responsible for an estimated 5 out of 10...

AI Technical Summary

Problems solved by technology

Multiple anti-inflammatory drugs have been tested with little or no efficacy in switching microglia from the M1 state to the M2 state

Images